Publish date:

FDA Approves Avanir Drug

Avanir's Nuedexta will be marketed as a treatment for pseudobulbar affect.



) --The U.S. Food and Drug Administration approved

Avanir Pharmaceuticals'

TST Recommends

Nuedexta for the treatment of pseudobulbar affect, an FDA spokesperson said in an email Friday night.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.